NASDAQ:CRVS Corvus Pharmaceuticals Q1 2026 Earnings Report $14.39 -0.26 (-1.77%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Corvus Pharmaceuticals EPS ResultsActual EPS-$0.15Consensus EPS -$0.14Beat/MissMissed by -$0.01One Year Ago EPSN/ACorvus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACorvus Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateThursday, May 7, 2026Conference Call Time4:00PM ETUpcoming EarningsCorvus Pharmaceuticals' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Corvus Pharmaceuticals Earnings HeadlinesCorvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare ConferenceSeptember 3 at 8:30 AM | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 3 at 2:15 AM | americanbankingnews.comThe ultimate IPO unicorn before Labor DayAnthropic is now valued at over $1 trillion, more than every U.S. airline combined and larger than the U.S. defense budget. Its annualized revenue grew 80x in the first quarter, and an IPO could arrive as early as October. For a limited time, investors can access a report detailing how to explore a pre-IPO stake in Anthropic for $29, a 94% discount off the retail price. The package includes a year of Disruptors and Dominators, monthly stock ideas, and four special reports.September 6 at 1:00 AM | Weiss Ratings (Ad)Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis TreatmentAugust 27, 2026 | seekingalpha.comCorvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma TrialAugust 27, 2026 | finance.yahoo.comCorvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma TrialAugust 27, 2026 | globenewswire.comSee More Corvus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corvus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corvus Pharmaceuticals and other key companies, straight to your email. Email Address About Corvus PharmaceuticalsCorvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes. Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape. Among these programs is an adenosine A2A receptor antagonist and a CD73-targeting monoclonal antibody, each advancing through Phase 1 and Phase 2 clinical trials. Additionally, the company is developing an ITK inhibitor aimed at enhancing T-cell activation. These assets are being evaluated both as monotherapies and in combination with checkpoint inhibitors across a range of solid tumor indications. The company conducts its clinical trials in multiple regions, with ongoing studies in the United States and Europe. Corvus collaborates with leading academic centers and oncology consortia to accelerate trial enrollment and leverage translational research insights. This global trial footprint supports the company’s strategy of generating robust clinical data and exploring combination regimens that may address high-unmet-need cancers such as non–small cell lung cancer, renal cell carcinoma and colorectal cancer. Founded in 2006 and headquartered in Carlsbad, California, Corvus Pharmaceuticals leverages a leadership team with extensive experience in oncology drug development, regulatory affairs and commercial strategy. Since its inception, the company has built a proprietary discovery platform and advanced multiple compounds from concept through early-stage clinical testing. As a Nasdaq-listed entity (NASDAQ: CRVS), Corvus continues to prioritize innovation in cancer immunotherapy with the goal of delivering meaningful new treatment options to patients worldwide.View Corvus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story3 Stocks With September Catalysts Investors Shouldn’t IgnoreOllie's Bargain Outlet Stock Falls on Weak Comps Despite Margin GainsWhy Hewlett Packard Enterprise’s Sell-Off May Not LastSnowflake’s AI Momentum Is Forcing a Fresh Look at the Stock Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
